<!doctype html>
<html class="no-js" lang="en">
  <head>
    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-55424252-12"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'UA-55424252-12');
    </script>
    <meta charset="utf-8">
    <meta http-equiv="x-ua-compatible" content="ie=edge">
    <title>RaQualia Pharma Pipeline [4579] - Ariafloat Stock</title>
    <meta name="description" content="RaQualia Pharma Pipeline [4579]">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <link rel="icon" type="image/png" href="../../img/boundcat-icon.png">
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0-beta.2/css/bootstrap.min.css" integrity="sha384-PsH8R72JQ3SOdhVi3uxftmaW6Vc51MKb0q5P2rRUpPvrszuE4W1povHYgTpBfshb" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/normalize/7.0.0/normalize.min.css">
    <link rel="stylesheet" href="../../css/main.css">
    <link rel="stylesheet" href="../css/raqualia.css">
    <!-- Google AdSense -->
    <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
    <script>
      (adsbygoogle = window.adsbygoogle || []).push({
        google_ad_client: "ca-pub-6825342955400774",
        enable_page_level_ads: true
      });
    </script>
    <!-- Google AdSense  -->
  </head>
  <body id="top">
    <nav class="navbar navbar-expand-lg navbar-dark bg-dark">
      <div class="container">
        <a class="navbar-brand" href="https://stock.ariafloat.com/">Ariafloat Stock</a>
        <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
          <span class="navbar-toggler-icon"></span>
        </button>
        <div class="collapse navbar-collapse" id="navbarNav">
          <ul class="navbar-nav ml-md-auto">
            <li class="nav-item">
              <a class="nav-link" href="https://stock.ariafloat.com/raqualia/">Japanese</a>
            </li>
            <li class="nav-item">
              <a class="nav-link" href="https://stock.ariafloat.com/raqualia/en/">Top</a>
            </li>
          </ul>
        </div>
      </div>
    </nav>    
    <main role="main" style="text-align: center;">
      <h1 style="text-align: center;">RaQualia Pharma [4579] </h1>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 2rem;">
        <div class="container">
          <h2 style="font-size: 1.3em"><a href="https://www.raqualia.com/" target="_blank" rel="nofollow" style="text-decoration: underline;">RaQualia Pharma Official Website</a></h2>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 2rem;">
        <div class="container">
          <h2 style="font-size: 1.7em"><a href="https://stock.ariafloat.com/raqualia/news/" style="text-decoration: underline;">NEWS</a></h2>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem;">
        <div class="container">
          <h2 style="font-size: 1.7em">RaQualia Pharma Research Report</h2>
          <ul style=" max-width: 350px; margin: 0 auto; text-align: left;">
            <li><a href="http://www.fisco.co.jp/uploads/raqualia20180629_e.pdf" target="_blank" rel="nofollow">FISCO Report [6/29, 2018]</a></li>
            <li><a href="https://search.sbisec.co.jp/v2/popwin/info/stock/market_report_btn_180320_01.pdf" target="_blank" rel="nofollow">SBI SECURITIES Report [3/20, 2018]</a></li>
            <li><a href="https://www.raqualia.co.jp/topics/20170704_002568.html" target="_blank" rel="nofollow">RaQualia Pharma, market capitalization to 100 billion yen in 20 years [7/4, 2017]</a></li>
          </ul>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">Pipelines</h2>
          <p>Updated on 8 15, 2019</p>
          <div class="pipeline-arrow-example-en">
            <div class="pipeline-arrow-end-legend-en">Completed</div>
            <div class="pipeline-arrow-prepared-legend-en">On planning</div>
            <div class="pipeline-arrow-legend-en">On going</div><div class="pipeline-arrow-example-clearboth"></div>
            <div class="pipeline-arrow-sale-legend-en">Launch</div>
            <div class="pipeline-arrow-plan-legend-en">Plan</div>
            <div style="clear: both;"></div>
          </div>
          <div class="scrollbooster-viewport-pipeline">
            <table class="table-simple table-pipeline scrollbooster-viewport-content-pipeline">
              <colgroup>
                <col span="1" style="width: 140px;">
                <col span="1" style="width: 117px;">
                <col span="1" style="width: 135px;">
                <col span="1" style="width: 110px;">
                <col span="8" style="width: 62px;">
                <col span="1" style="width: 75px;">
                <col span="1" style="width: 255px;">
              </colgroup>
              <thead>
                <tr>
                  <th rowspan="2">Project</th>
                  <th rowspan="2">Compound code<br>(Generic name)</th>
                  <th rowspan="2">Indication</th>
                  <th rowspan="2">Partnered party</th>
                  <th rowspan="2">Discovery</th>
                  <th rowspan="2">Pre-Clin,</th>
                  <th colspan="3">Clinical Trial</th>
                  <th rowspan="2">NDA</th>
                  <th rowspan="2">Approval</th>
                  <th rowspan="2">Launch</th>
                  <th rowspan="2">Territory</th>
                  <th rowspan="2">Remarks</th>
                </tr>
                <tr style="font-size: 0.9em;">
                  <th>Phase 1</th>
                  <th>Phase 2</th>
                  <th>Phase 3</th>                    
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="7"><a href="https://stock.ariafloat.com/raqualia/pipeline/tegoprazan.html">PotassiumCompetitive acid blocker<br>(P-CAB)</a></td>
                  <td rowspan="7">RQ-00000004<br>(Tegoprazan)<br>CJ-12420 [CJ HealthCare]<br>LXI-15028 [Luoxin Pharma]</td>
                  <td rowspan="7">GERD<br>(ERD/NERD)<br>Gastric ulcer</td>
                  <td>-</td>
                  <td colspan="3"><div class="pipeline-arrow-end">Completed P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA<br>Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td rowspan="6">CJ HealthCare</td>
                  <td colspan="8"><div class="pipeline-arrow-sale">Launch (March 2019)</div></td>
                  <td>Korea</td>
                  <td class="text-left pipeline-option">
                    Product name: K-CAB<br>
                    Co-promotion with Chong Kun Dang Pharmaceutical Corp.<br>
                    <a href="https://www.raqualia.co.jp/topics/20170707_002569.html" target="_blank" rel="nofollow">Blockbuster expectation with annual sales of 100 billion won.</a>
                  </td>
                </tr>
                <tr>
                  <td colspan="5"><div class="pipeline-arrow">On going P3</div></td>
                  <td colspan="3"><div class="pipeline-arrow-plan2">Launch<br>2021-2022</div></td>
                  <td>China</td>
                  <td class="text-left pipeline-option">Re-contracted: CJ HealthCare => Luoxin Pharma<br>Market Size (China): 260 billion yen (2 billion 600 million USD) *Investigation of RaQualia</td>
                </tr>
                <tr>
                  <td colspan="6"><div class="pipeline-arrow-prepared">Preparation NDA</div></td>
                  <td colspan="2"><div class="pipeline-arrow-plan2">Launch<br>2021</div></td>
                  <td>Vietnam</td>
                  <td class="text-left pipeline-option">Re-contracted: CJ HealthCare => Vimedimex Medi-Pharma JSC<br><a href="https://www.raqualia.co.jp/ir/files/20181221170000_599781/library_%E8%83%83%E9%A3%9F%E9%81%93%E9%80%86%E6%B5%81%E7%97%87%E6%B2%BB%E7%99%82%E8%96%ACtegoprazan%E3%81%AE%E3%83%99%E3%83%88%E3%83%8A%E3%83%A0%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E3%82%B5%E3%83%96%E3%83%A9%E3%82%A4%E3%82%BB%E3%83%B3%E3%82%B9%E5%A5%91%E7%B4%84%E7%B7%A0%E7%B5%90%E4%B8%A6%E3%81%B3%E3%81%AB%E4%B8%80%E6%99%82%E9%87%91%E5%8F%97%E9%A0%98%E3%81%AE%E3%81%8A%E7%9F%A5%E3%82%89%E3%81%9B.pdf" target="_blank" rel="nofollow">Related information</a></td>
                </tr>
                <tr>
                  <td colspan="6"><div class="pipeline-arrow-prepared">Preparation NDA</div></td>
                  <td colspan="2"><div class="pipeline-arrow-plan2">Launch<br>2022 (Mexico)</div></td>
                  <td>Latin America<br>17 countries<br>(Mexico, Argentina etc.)</td>
                  <td class="text-left pipeline-option">Re-contracted: CJ HealthCare => Laboratorios Carnot<br><a href="https://www.raqualia.co.jp/ir/files/20190213123000_608665/library_%E8%83%83%E9%A3%9F%E9%81%93%E9%80%86%E6%B5%81%E7%97%87%E6%B2%BB%E7%99%82%E8%96%ACtegoprazan%E3%81%AE%E4%B8%AD%E5%8D%97%E7%B1%B3%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E3%82%B5%E3%83%96%E3%83%A9%E3%82%A4%E3%82%BB%E3%83%B3%E3%82%B9%E5%A5%91%E7%B4%84%E7%B7%A0%E7%B5%90%E4%B8%A6%E3%81%B3%E3%81%AB%E4%B8%80%E6%99%82%E9%87%91%E5%8F%97%E9%A0%98%E3%81%AE%E3%81%8A%E7%9F%A5%E3%82%89%E3%81%9B.pdf" target="_blank" rel="nofollow">Related information</a></td>
                </tr>
                <tr>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>ROW</td>
                  <td class="text-left pipeline-option">ROW: Latin America (Brazil etc.), East European, Middle East</td>
                </tr>
                <tr>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Taiwan<br>Southeast Asia</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>CRHR2 antagonist</td>
                  <td>-</td>
                  <td>Heart failure</td>
                  <td>Nagoya University<br>(Collaborative Research)</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option">
                    Discovered lead compounds and started an investigation of preclinical efficacy.<br>
                    This research plans to complete the research phase from the end of 2019 to 2020. <a href="https://www.raqualia.co.jp/topics/20190225_003922.html" target="_blank" rel="nofollow">[Reference]</a>
                  </td>
                </tr>
                <tr>
                  <td><a href="https://stock.ariafloat.com/raqualia/pipeline/trpm8-blocker.html">TRPM8 blocker</a></td>
                  <td>RQ-00434739</td>
                  <td>Neuropathic pain</td>
                  <td>-</td>
                  <td colspan="2"><div class="pipeline-arrow-prepared">On planning</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>P2X7 receptor antagonist</td>
                  <td>RQ-00466479<br>AKP-23494954 [Asahi Kasei Pharma]</td>
                  <td>Neuropathic pain</td>
                  <td>Asahi Kasei Pharma</td>
                  <td colspan="2"><div class="pipeline-arrow">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Global</td>
                  <td class="text-left pipeline-option">Diabetic neuropathic medicine, herpes virus infective neuropathic medicine. It is conducting tests to establish long-term toxicity tests and industrial synthesis methods. Clinical trial schedule for people in 2019. <a href="https://newswitch.jp/p/13022" target="_blank" rel="nofollow">[Reference]</a></td>
                </tr>
                <tr>
                  <td rowspan="2">Selective sodium channel blocker</td>
                  <td>-</td>
                  <td>Analgesia<br>Pruritus</td>
                  <td>Maruho</td>
                  <td colspan="2"><div class="pipeline-arrow">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Global</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>-</td>
                  <td>Pain</td>
                  <td>-</td>
                  <td><div class="pipeline-arrow3">Discovery</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Specific Ion Channels</td>
                  <td>-</td>
                  <td>Gastrointestinal Tract</td>
                  <td>EA Pharma</td>
                  <td colspan="2"><div class="pipeline-arrow">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Global</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Specific Ion Channels</td>
                  <td>-</td>
                  <td>-</td>
                  <td>ASKA Pharmaceutical<br>(Collaborative Research)</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Sodium channel Nav1.7 selective blocker</td>
                  <td>RQ-00488738</td>
                  <td>Pain</td>
                  <td>-</td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option">Product of collaboration with XuanZhu Pharma</td>
                </tr>
                <tr>
                  <td>protein-protein interaction inhibitor</td>
                  <td>On Identity Test</td>
                  <td>Pain</td>
                  <td>Interprotein<br>(Collaborative Research)</td>
                  <td><div class="pipeline-arrow3">On going</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>-</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td rowspan="3">5-HT4 partial agonist</td>
                  <td rowspan="2">RQ-00000010</td>
                  <td>Gastroparesis<br>Functional dyspepsia<br>Chronic Constipation</td>
                  <td>-</td>
                  <td colspan="3"><div class="pipeline-arrow-end">Completed P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>UK</td>
                  <td class="text-left pipeline-option">Mosapride's sales amount of peak tops is 21.2 billion yen (Japan)</td>
                </tr>
                <tr>
                  <td>Gastroparesis</td>
                  <td>-</td>
                  <td colspan="3"><div class="pipeline-arrow">Investigator Clinical Trial</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option">Collaboration with Virginia Commonwealth University (VCU) Parkinson's and Movement Disorders Center</td>
                </tr>
                <tr>
                  <td>RQ-00000009<br>AAT-009 [AskAt]</td>
                  <td>Alzheimer's</td>
                  <td>AskAt</td>
                  <td colspan="3"><div class="pipeline-arrow-end">Completed P1 (U.S.)</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Global</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>5-HT2B antagonist</td>
                  <td>RQ-00310941</td>
                  <td>IBS-D</td>
                  <td>-</td>
                  <td colspan="3"><div class="pipeline-arrow-end">Completed P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>UK</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Motilin receptor agonist</td>
                  <td>RQ-00201894</td>
                  <td>Gastroparesis<br>Functional dyspepsia<br>Post - operative Ileus</td>
                  <td>-</td>
                  <td colspan="3"><div class="pipeline-arrow-prepared">On planning P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td rowspan="3">Ghrelin receptor agonist</td>
                  <td rowspan="2"><a href="https://stock.ariafloat.com/raqualia/pipeline/ghrelin-receptor-agonist-rq-00000005.html">RQ-00000005<br>（Capromorelin）<br>AT-002 [Aratana]</a></td>
                  <td>Weight loss, Anorexia: Dog</td>
                  <td rowspan="2">Aratana Therapeutics<br>(Global (Animal))</td>
                  <td colspan="8"><div class="pipeline-arrow-sale">Launch (October 2017)</div></td>
                  <td>USA</td>
                  <td rowspan="2" class="text-left pipeline-option">Product name: Entyce®</td>
                </tr>
                <tr>
                  <td>Weight loss, Anorexia: Cat</td>
                  <td colspan="5"><div class="pipeline-arrow">Pivotal study</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                </tr>
                <tr>
                  <td>RQ-00433412</td>
                  <td>Anorexia associated with cancer</td>
                  <td>-</td>
                  <td colspan="2"><div class="pipeline-arrow-prepared">On planning</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Ziprasidone</td>
                  <td>RQ-00000003<br>(Ziprasidone Hydrochloride Monohydrate)<br>ME2112 [Meiji Seika Pharma]</td>
                  <td>Schizophrenia</td>
                  <td>Meiji Seika Pharma</td>
                  <td colspan="5"><div class="pipeline-arrow">On going P3</div></td>
                  <td><div class="pipeline-arrow-plan2">NDA<br>2019</div></td>
                  <td colspan="2"><div class="pipeline-arrow-plan2">Launch<br>2020</div></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option">Market Size (Japan): 160 Billion Yen *Investigation of RaQualia</td>
                </tr>
                <tr>
                  <td rowspan="9">EP4 antagonist</td>
                  <td rowspan="6"><a href="https://stock.ariafloat.com/raqualia/pipeline/ep4-antagonist-rq-00000007.html">RQ-00000007<br>（Grapiprant）<br>AAT-007 [AskAt]<br>AT-001 [Aratana]<br>ARY-007 [Arrys]<br>RMX1002 [RMX]</a></td>
                  <td>Osteoarthritis: Dog</td>
                  <td>Aratana Therapeutics<br>(Global (Animal))</td>
                  <td colspan="8"><div class="pipeline-arrow-sale">Launch (USA: Jan. 2017, Europe: Mar. 2019)</div></td>
                  <td>USA<br>Europe</td>
                  <td class="text-left pipeline-option">Product name: Galliprant®<br>With this product Aratana makes strategic alliance with Elanco</td>
                </tr>
                <tr>
                  <td>MSS Colorectal Cancer</td>
                  <td rowspan="5">AskAt<br>(Global (Excluding animal))</td>
                  <td colspan="3"><div class="pipeline-arrow"><a href="https://clinicaltrials.gov/ct2/show/NCT03658772" target="_blank" rel="nofollow" class="pipeline-arrow-link">On going P1b</a></div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td rowspan="2">USA</td>
                  <td rowspan="2" class="text-left pipeline-option">Re-contracted: AskAt => Arrys Therapeutics (Global excluding China and Taiwan)<br>Development: Arrys affiliate <a href="https://kyntherapeutics.com/" target="_blank" rel="nofollow">Kyn Therapeutics</a><br>Clinical study with grapiprant in combination with pembrolizumab(anti PD-1 antibody, KEYTRUDA).</td>
                </tr>
                <tr>
                  <td>NSCLC Adenocarcinoma</td>
                  <td colspan="3"><div class="pipeline-arrow"><a href="https://clinicaltrials.gov/ct2/show/NCT03696212" target="_blank" rel="nofollow" class="pipeline-arrow-link">On going P1b/2</a></div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                </tr>
                <tr>
                  <td>Cancer</td>
                  <td colspan="3"><div class="pipeline-arrow">On going P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>China</td>
                  <td class="text-left pipeline-option">Re-contracted: AskAt => Ningbo Tai Kang Medical Technology<br>Development: Ningbo NewBay Medical Technology</td>
                </tr>
                <tr>
                  <td rowspan="2">Pain</td>
                  <td colspan="4"><div class="pipeline-arrow-end">Completed P2a</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td colspan="3"><div class="pipeline-arrow-end">Completed P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>China</td>
                  <td class="text-left pipeline-option">Re-contracted: AskAt => RMX Biopharma<br>Development: A joint venture between Shanghai HaiHe Biopharma and China Shijiazhuang Holding Group <a href="http://en.haihepharma.com/haihe_en/vip_doc/12399249.html" target="_blank" rel="nofollow">[Reference]</a></td>
                </tr>
                <tr>
                  <td rowspan="3"><a href="https://stock.ariafloat.com/raqualia/pipeline/ep4-antagonist-rq-00000008.html">RQ-00000008<br>AAT-008 [AskAt]<br>AT-019 [Aratana]</a></td>
                  <td>Animal</td>
                  <td rowspan="3">AskAt<br>(Global)</td>
                  <td colspan="5"><div class="pipeline-arrow2">Started transferring the manufacturing process of the API and early formulation work (early-2019)</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Global</td>
                  <td class="text-left pipeline-option">Re-contracted: AskAt => Aratana</td>
                </tr>
                <tr>
                  <td rowspan="2">Cancer</td>
                  <td colspan="3"><div class="pipeline-arrow-prepared">On planning P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option">Re-contracted: AskAt => Arrys Therapeutics (Global excluding China and Taiwan)</td>
                </tr>
                <tr>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>China</td>
                  <td class="text-left pipeline-option">Re-contracted: AskAt => Ningbo NewBay Medical Technology</td>
                </tr>
                <tr>
                  <td rowspan="2">COX-2 Inhibitor</td>
                  <td rowspan="2">RQ-00317076<br>AAT-076 [AskAt]<br>RMX1001 [RMX]</td>
                  <td rowspan="2">Acute Pain</td>
                  <td rowspan="2">AskAt<br>(Global)</td>
                  <td colspan="4"><div class="pipeline-arrow-end">Completed P2a</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td colspan="3"><div class="pipeline-arrow-prepared">On planning P1</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>China</td>
                  <td class="text-left pipeline-option">Re-contracted: AskAt => RMX Biopharma<br>Development: A joint venture between Shanghai HaiHe Biopharma and China Shijiazhuang Holding Group <a href="http://en.haihepharma.com/haihe_en/vip_doc/12399249.html" target="_blank" rel="nofollow">[Reference]</a></td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">Other Pipelines</h2>
          <p>Updated on 4 5, 2019</p>
          <div class="scrollbooster-viewport-pipeline-other-en">
            <table class="table-simple table-pipeline-other-en scrollbooster-viewport-content-pipeline-other-en">
              <colgroup>
                <col span="1" style="width: 140px;">
                <col span="1" style="width: 100px;">
                <col span="1" style="width: 100px;">
                <col span="1" style="width: 70px;">
                <col span="1" style="width: 130px;">
              </colgroup>
              <thead>
                <tr>
                  <th>Project</th>
                  <th>Indication</th>
                  <th>Partnered party</th>
                  <th>Territory</th>
                  <th>Remarks</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>CB2 agonist</td>
                  <td>Pain<br>Immunology</td>
                  <td>AskAt</td>
                  <td>？</td>
                  <td></td>
                </tr>
                <tr>
                  <td>Dalbavancin</td>
                  <td>MRSA Infections</td>
                  <td>-</td>
                  <td>Japan</td>
                  <td>US product name: Dalvance</td>
                </tr>
                <tr>
                  <td>Anidulafungin</td>
                  <td>Candida Infections</td>
                  <td>-</td>
                  <td>Japan</td>
                  <td>US product name: Eraxis</td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">Other Contracts</h2>
          <p>Updated on 12 15, 2018</p>
          <div class="scrollbooster-viewport-contract-other">
            <table class="table-simple table-contract-other scrollbooster-viewport-content-contract-other">
              <colgroup>
                <col span="1" style="width: 120px;">
                <col span="1" style="width: 500px;">
                <col span="1" style="width: 110px;">
              </colgroup>
              <thead>
                <tr>
                  <th>Contractor</th>
                  <th>Contract contents</th>
                  <th>Remarks</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>H. Lundbeck A/S<br>(Denmark)</td>
                  <td>RaQualia Grants Patent License to H. Lundbeck</td>
                  <td><a href="https://www.raqualia.co.jp/topics/uploads/10239957dd48f8d431d806e8be9b1f8e.pdf" target="_blank" rel="nofollow">Press release</a></td>
                </tr>
                <tr>
                  <td>Shire AG<br>(Swiss)</td>
                  <td>RaQualia Grants a Non-Exclusive Patent License to Shire AG For the Use of Ghrelin Receptor Agonist</td>
                  <td><a href="https://www.raqualia.co.jp/topics/20110216_002060.html" target="_blank" rel="nofollow">Press release</a></td>
                </tr>
                <tr>
                  <td>-</td>
                  <td>RaQualia Pharma Joins DeNA & DeNA Life Science AI-Powered Drug Discovery Research Collaboration</td>
                  <td><a href="https://www.raqualia.com/topics/uploads/f13edde83fd8bb9183b935ea829416f8.pdf" target="_blank" rel="nofollow">Press release</a></td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">University Collaborative Research</h2>
          <p>Updated on 8 16, 2019</p>
          <a href="http://www.riem.nagoya-u.ac.jp/4/rcrc/" target="_blank" rel="nofollow">RaQualia Pharma Industry-Academia Collaborative Research Center</a>
          <br><br>
          <div class="scrollbooster-viewport-university">
            <table class="table-simple table-university scrollbooster-viewport-content-university">
              <colgroup>
                <col span="1" style="width: 110px;">
                <col span="1" style="width: 250px;">
                <col span="1" style="width: 300px;">
                <col span="1" style="width: 200px;">
              </colgroup>
              <thead>
                <tr>
                  <th>University</th>
                  <th>Department</th>
                  <th>Research theme</th>
                  <th>Remarks</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="5">Nagoya University</td>
                  <td>Department of Biochemistry, Graduate School of Medicine</td>
                  <td>Search for selective inhibitors targeting specific enzymes for treatment of refractory neuroblastoma</td>
                  <td><a href="https://www.raqualia.co.jp/topics/20150529_002386.html" target="_blank" rel="nofollow">Press release</a></td>
                </tr>
                <tr>
                  <td>Department of Cardiology, Graduate School of Medicine</td>
                  <td>Search for selective inhibitors targeting specific proteins for treatment of heart failure</td>
                  <td>
                    <a href="https://www.raqualia.co.jp/topics/20151112_002435.html" target="_blank" rel="nofollow">Press release</a><br>
                  </td>
                </tr>
                <tr>
                  <td>Department of Respiratory Medicine, Graduate School of Medicine</td>
                  <td>Search for novel therapeutic agents for KRAS mutated lung cancer</td>
                  <td><a href="https://www.raqualia.co.jp/topics/20180126_002619.html" target="_blank" rel="nofollow">Press release</a></td>
                </tr>
                <tr>
                  <td>Department of Brain Function, Research Institute for Environmental Medicine</td>
                  <td>Mass spectrometry imaging and characterization of TRPM8 blocker RQ-00434739 in the brain</td>
                  <td><a href="https://www.raqualia.co.jp/topics/20181003_003884.html" target="_blank" rel="nofollow">Press release</a></td>
                </tr>
                <tr>
                  <td>Department of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine</td>
                  <td>Characterization of the mechanism of action of a novel small molecule compound targeting non-alcoholic steatohepatitis (NASH)</td>
                  <td><a href="https://www.raqualia.co.jp/topics/20181003_003883.html" target="_blank" rel="nofollow">Press release</a></td>
                </tr>
                <tr>
                  <td>Nagoya City University</td>
                  <td>Department of Biomedical Science, Graduate School of Pharmaceutical Sciences</td>
                  <td>Discovery of novel small molecules for the treatment of Amyotrophic Lateral Sclerosis (ALS)</td>
                  <td><a href="https://www.raqualia.co.jp/topics/20190701_003964.html" target="_blank" rel="nofollow">Press release</a></td>
                </tr>
                <tr>
                  <td>Gifu Pharmaceutical University</td>
                  <td>Molecular Pharmacology, Department of Biofunctional Evaluation</td>
                  <td>Evaluation of efficacy of a specific compound on retinal vein occlusion (RVO)</td>
                  <td><a href="https://www.raqualia.co.jp/topics/20190530_003943.html" target="_blank" rel="nofollow">Press release</a></td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">TMRC (subsidiary) Pipeline</h2>
          <p>Updated on 8 15, 2019</p>
          <div class="pipeline-arrow-example-en">
            <div class="pipeline-arrow-end-legend-en">Completed</div>
            <div class="pipeline-arrow-prepared-legend-en">On planning</div>
            <div class="pipeline-arrow-legend-en">On going</div><div class="pipeline-arrow-example-clearboth"></div>
            <div class="pipeline-arrow-sale-legend-en">Launch</div>
            <div class="pipeline-arrow-plan-legend-en">Plan</div>
            <div style="clear: both;"></div>
          </div>
          <div class="scrollbooster-viewport-pipeline">
            <table class="table-simple table-pipeline scrollbooster-viewport-content-pipeline">
              <colgroup>
                <col span="1" style="width: 140px;">
                <col span="1" style="width: 117px;">
                <col span="1" style="width: 135px;">
                <col span="1" style="width: 110px;">
                <col span="8" style="width: 62px;">
                <col span="1" style="width: 75px;">
                <col span="1" style="width: 255px;">
              </colgroup>
              <thead>
                <tr>
                  <th rowspan="2">Project</th>
                  <th rowspan="2">Compound code<br>(Generic name)</th>
                  <th rowspan="2">Indication</th>
                  <th rowspan="2">Partnered party</th>
                  <th rowspan="2">Discovery</th>
                  <th rowspan="2">Pre-Clin,</th>
                  <th colspan="3">Clinical Trial</th>
                  <th rowspan="2">NDA</th>
                  <th rowspan="2">Approval</th>
                  <th rowspan="2">Launch</th>
                  <th rowspan="2">Territory</th>
                  <th rowspan="2">Remarks</th>
                </tr>
                <tr style="font-size: 0.9em;">
                  <th>Phase 1</th>
                  <th>Phase 2</th>
                  <th>Phase 3</th>                    
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td rowspan="5">TM-411</td>
                  <td rowspan="5">TM-411<br>(Tamibarotene)<br>SY-1425 [Syros Pharmaceuticals]<br>OP-09 [Ohara Pharmaceutical]</td>
                  <td>Newly diagnosed unfit AML</td>
                  <td rowspan="2">Syros Pharmaceuticals</td>
                  <td colspan="4"><div class="pipeline-arrow">On going P2 (Multiple drug combination)</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td rowspan="2" class="text-left pipeline-option">Combination with azacitidine.<a href="https://ir.syros.com/press-releases/detail/148/syros-announces-promising-clinical-data-from-ongoing" target="_blank" rel="nofollow">Initial data</a>.</td>
                </tr>
                <tr>
                  <td>Relapsed or refractory AML</td>
                  <td colspan="4"><div class="pipeline-arrow">On going P2 (Multiple drug combination)</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                </tr>
                <tr>
                  <td>Neuroblastoma<br>(NB)</td>
                  <td>Ohara Pharmaceutical</td>
                  <td colspan="3"><div class="pipeline-arrow">On going P1/2</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>Japan</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Acute promyelocytic leukemia<br>(APL)</td>
                  <td>Toko Pharmaceutical Industrial</td>
                  <td colspan="6"><div class="pipeline-arrow">NDA</div></td>
                  <td></td>
                  <td></td>
                  <td>China</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
                <tr>
                  <td>Neutropenia<br>(NP)</td>
                  <td>-</td>
                  <td colspan="2"><div class="pipeline-arrow-end">Completed</div></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td></td>
                  <td>USA</td>
                  <td class="text-left pipeline-option"></td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 3rem; padding-bottom: 3rem;">
        <div class="container-pipeline">
          <h2 style="font-size: 1.7em">Subsidiary</h2>
          <p>Updated on 4 24, 2019</p>
          <table class="table-simple table-subsidiary">
            <colgroup>
              <col span="1">
            </colgroup>
            <thead>
              <tr>
                <th>Company name</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td><a href="http://www.tmrc.co.jp/english/index.html" target="_blank" rel="nofollow">TMRC Co., Ltd.</a></td>
              </tr>
              <tr>
                <td><a href="https://www.raqinnovations.co.jp/" target="_blank" rel="nofollow">RaQualia Innovations Inc.</a></td>
              </tr>
            </tbody>
          </table>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 1rem; padding-bottom: 1rem;">
        <div class="container" style="max-width: 700px;">
          <p>Because of the personal survey, there are cases where the information on this site is "different from the fact" due to business content change or misunderstanding etc.<br>Therefore, please do not use for investment judgment. Also, this site is not intended to solicit investment.</p>
        </div>
      </section>
      <section class="text-center" style="background-color: #FFFFFF; padding-top: 1rem; padding-bottom: 1rem;">
        <div class="container">
          <!-- Google AdSense -->
          <div id="adsense" style="width: 70%; margin: 0px auto; text-align: center;">
            <h6>Advertisements</h6>
            <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
            <!-- レスポンシブ広告 -->
            <ins class="adsbygoogle"
                 style="display:block"
                 data-ad-client="ca-pub-6825342955400774"
                 data-ad-slot="1464182490"
                 data-ad-format="auto"
                 data-full-width-responsive="true"></ins>
            <script>
            (adsbygoogle = window.adsbygoogle || []).push({});
            </script>
          </div>
        </div>
      </section>
    </main>
    <footer class="text-muted" style="background-color: #F2F2F2;">
      <div class="container">
        <p class="float-right">
          <a class="none-a" href="#top">Page top</a>
        </p>
        <p><a class="none-toppage" href="https://stock.ariafloat.com/">&copy; Ariafloat Stock.</a>
        </p>
      </div>
    </footer>
    <script src="../../js/vendor/modernizr-3.5.0.min.js"></script>
    <script src="https://code.jquery.com/jquery-3.2.1.min.js" integrity="sha256-hwg4gsxgFZhOsEEamdOYGBf13FyQuiTwlAQgxVSNgt4=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.3/umd/popper.min.js" integrity="sha384-vFJXuSJphROIrBnz7yo7oB41mKfc8JzQZiCq4NCceLEaO4IHwicKwpJf9c9IpFgh" crossorigin="anonymous"></script>
    <script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0-beta.2/js/bootstrap.min.js" integrity="sha384-alpBpkh1PFOepccYVYDB4do5UnbKysX5WZXm3XxPqe5iKTfUKjNkCk9SaVuEZflJ" crossorigin="anonymous"></script>
    <script src="../../js/plugins.js"></script>
    <script src="../../js/main.js"></script>
    <script src="../js/responsive.js"></script>
  </body>
</html>
